#United States #BD #Franklin Lakes #Becton #Dickinson

BD Reports First Quarter Fiscal 2025 Financial Results

BD (Becton, Dickinson and Company), a prominent player in the global medical technology landscape, recently shared its financial outcomes for the first quarter of fiscal 2025, which ended on December 31, 2024. The company reported a total revenue of $5.2 billion, marking a notable 9.8% increase compared to the previous year. This growth is largely attributed to a strategic focus on operational excellence and innovation.

Highlights from Q1 Fiscal 2025

• - Revenue Gains: BD experienced a 9.6% increase in revenue on a currency-neutral basis, with an organic growth rate of 3.9%. The growth reflects substantial momentum across all business segments, especially in medication delivery solutions.
• - Earnings Growth: The reported diluted earnings per share (EPS) stood at $1.04, indicating an 8.3% rise, while the adjusted diluted EPS reached $3.43, up 28% from the previous year.
• - Share Repurchase Program: BD has actively engaged in share repurchases, completing a $750 million buyback within the fiscal year to date, showing their commitment to returning value to shareholders.

Operations and Future Outlook

Tom Polen, BD’s CEO, articulated a robust operational performance, emphasizing the company's ongoing transformation strategy, known as BD 2025. This strategy includes plans to separate the Biosciences and Diagnostic Solutions divisions to maximize growth and unlock value for shareholders. The separation aims to allow each segment to focus more intently on innovation and operational excellence independently.

Business Operations Breakdown

• - BD Medical: This segment achieved revenues of $2.6 billion, marking a 17.3% year-over-year increase, driven primarily by the Medication Delivery Solutions unit, which saw surging demand for critical medical supplies.
• - BD Life Sciences: With revenues nearing $1.3 billion, this division faced modest growth, yet its innovations in specimen management and diagnostics continue to position it as a key player within the healthcare sector. Notably, the approval of the BD Onclarity™ HPV Assay by the FDA strengthens its diagnostic offerings, addressing critical health concerns such as cervical cancer.
• - BD Interventional: Reporting revenues of $1.2 billion, this segment grew by 5.8%, supported by solid performance across surgical and urological interventions.

Guidance and Expectations for FY2025

Looking forward, BD has raised its fiscal 2025 guidance for adjusted diluted EPS to between $14.30 and $14.60, projecting an average growth of 10% at the midpoint. This guidance includes adjustments to accommodate the estimated impact of foreign currency translation.

Conclusion

BD's acquisition of stellar revenue growth in the first quarter, alongside a commitment to innovation and strategic restructuring, positions the company confidently for FY2025. As it navigates the complexities of the global healthcare landscape, BD's focus remains clear: to enhance patient care and drive operational excellence through its advanced medical technologies. Investors and stakeholders will be keenly watching BD’s continued performance and its ability to deliver on its ambitious objectives as outlined during its earnings call.